The concept of targeted protein degradation presents
revolutionary drug development opportunities and is anticipated to bring about
a paradigm shift in modern healthcare. The first targeted
protein degrader, called proteolysis targeting chimera (PROTAC), was developed
about a decade ago. Presently, a variety of other such chemical entities and
molecular glues are under investigation. In fact, certain pipeline candidates are
already in the mid to late-phase trials and are anticipated to soon enter the
market.
To order this 330+
page report, which features 130+ figures and 145+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
The USD 3.6 billion (by 2030) financial opportunity
within the target protein degradation market has been analyzed across the
following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The Targeted
Protein Degradation Market: Focus on Therapeutics and Technology Platforms
(based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags,
IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic
Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors),
2020-2030
report
features the following companies, which we identified to be key players in this
domain:
§
§
§
§
§
§
§
§
§ Sanofi
Genzyme
§ Zenopharm
Table of Contents
1. Preface
4. Current Market Landscape
5. Company Profiles
6. Clinical Trial Analysis
7. KOL Analysis
8. Publication Analysis
9. Funding and Investment Analysis
10. Partnerships and Collaborations
11.
12. Executive Insights
13. Concluding Remarks
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and
Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
